

Cobimetinib Development Program

As of May 11, 2018. Not a full list of studies; see clinicaltrials.gov for a comprehensive list.

COBIMETINIB PHASE 3 DEVELOPMENT ACTIVITIES‡		
Indication / Disease State	Combination Regimen	Status Update
Metastatic or Unresectable Locally Advanced Melanoma		
BRAF mutation-positive	+ vemurafenib	Approved in U.S., EU and other territories
First-line BRAF mutation-positive	+ atezolizumab + vemurafenib	Phase 3 (IMspire150)*
First-line BRAF wild-type	+ atezolizumab	Phase 3 (IMspire170)*
Colorectal Cancer		
Third-line advanced or metastatic disease	+ atezolizumab	Per May 9th update, phase 3 (IMblaze370) trial did not meet its primary endpoint; Genentech plans to present data at upcoming medical meeting

‡ Cobimetinib is being evaluated in a broad development program consisting of more than 50 clinical trials by Genentech or through Genentech's investigator sponsored trial program. The trials indicated in the above table are all sponsored by Genentech.

* Ongoing clinical trial.

